Routine governance filing — no immediate trading catalyst. Monitor future 8-K filings for actual equity grant activity under the new plan, which could signal management's confidence or retention strategy.
Price Chart
Executive Summary
Xenon Pharmaceuticals filed an 8-K reporting the results of its June 2, 2026 annual meeting, where shareholders approved the new 2026 Equity Incentive Plan (replacing the 2014 plan), elected all eight director nominees, and approved say-on-pay and auditor appointments. The 2026 Plan authorizes up to 4.4 million new common shares plus a rollover of up to 14.72 million shares from the prior plan, providing long-term equity compensation capacity. This is a routine governance filing with no material financial impact.
Key Facts
- Shareholders approved the 2026 Equity Incentive Plan with 58,579,810 votes for, 27,570,443 against, and 842,250 abstentions.
- The 2026 Plan authorizes 4,400,000 new common shares plus up to 14,720,800 shares rolled over from the prior 2014 plan.
- All eight director nominees were elected with strong support (82.5M to 86.6M votes for each).
- Say-on-pay was approved with 82.2M votes for, 4.8M against.
- PricewaterhouseCoopers LLP was ratified as auditor with 90.4M votes for.
- 93.54% of outstanding common shares were represented at the meeting.
- The 2026 Plan replaces the Amended and Restated 2014 Equity Incentive Plan.
Financial Impact
No immediate financial impact. The 2026 Plan provides up to ~19.1M shares for future equity grants, but no specific grants were disclosed.
Risk Factors
- Potential future dilution from equity grants under the new plan, though amounts are not yet specified.
- The 27.6M votes against the 2026 Plan (32% of votes cast) indicate notable shareholder dissent, which may signal governance concerns.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-255396 |
| Document: xene-20260602.htm | 0001193125-26-255396 |
| Document: 0001193125-26-255396-index-headers.html | 0001193125-26-255396 |
| Document: 0001193125-26-255396-index.html | 0001193125-26-255396 |
| Document: 0001193125-26-255396.txt | 0001193125-26-255396 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 2, 2026 13w ago | Press Release | $60.96 $64.19 | ▲ +5.30% | ▲ +5.71% | $38.02 (−37.63%) |
Jun 5, 2026 17w ago | 144 | $51.21 $60.54 | ▲ +18.22% | ▲ +16.59% | $38.02 (−25.76%) |
Jun 3, 2026 17w ago | 8-K | $52.99 $60.96 | ▲ +15.04% | ▲ +16.41% | $38.02 (−28.25%) |
May 7, 2026 21w ago | Press Release | $56.44 $51.73 | ▼ −8.35% | ▼ −8.37% | $38.02 (−32.64%) |
Apr 22, 2026 23w ago | DEFA14A | $55.41 $54.68 | ▼ −1.32% | ▼ −5.95% | $38.02 (−31.38%) |
Apr 19, 2026 23w ago | Press Release | $57.09 $53.71 | ▼ −5.92% | ▼ −10.12% | $38.02 (−33.40%) |
Apr 15, 2026 24w ago | Press Release | $58.88 $55.00 | ▲ +6.59% | ▲ +12.63% | $38.02 (+35.43%) |
Apr 13, 2026 24w ago | 8-K | $59.35 $55.78 | ▼ −6.02% | ▼ −12.31% | $38.02 (−35.94%) |
Apr 7, 2026 25w ago | Press Release | $57.65 $57.40 | ▲ +0.43% | ▲ +10.21% | $38.02 (+34.05%) |
Mar 13, 2026 29w ago | Insider Cluster | $55.23 $58.60 | ▼ −6.10% | ▼ −2.51% | $38.02 (+31.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access